Clinical Trials Logo

Vaginal Abnormality clinical trials

View clinical trials related to Vaginal Abnormality.

Filter by:
  • None
  • Page 1

NCT ID: NCT06311812 Recruiting - Vaginal Abnormality Clinical Trials

Retrospective Review on Uterovaginal Anomalies

Start date: April 1, 2024
Phase:
Study type: Observational

Review of surgical outcomes of patient who have undergone surgery for uterovaginal anomalies. Case notes of patients would be reviewed and data would be gathered for statistical analysis.

NCT ID: NCT05381584 Not yet recruiting - Vaginal Abnormality Clinical Trials

Balloon Vaginoplasty for Treatment of Vaginal-aplasia

Start date: July 2022
Phase: N/A
Study type: Interventional

Vaginal aplasia is a congenital anomaly characterized by congenital absence of the vagina with an incidence approximately 1:4,500-6,000. It carries an emotional, sexual, and social embarrassing effect on those women, The primary aim of treatment is creation of a neo vagina for restoration of the ability for vaginal intercourse. There are several techniques for neo vaginal construction with variable satisfaction rates. Most of these procedures are either invasive and technically demanding or require long duration in a very motivated patient

NCT ID: NCT05165056 Recruiting - Clinical trials for Radiotherapy Side Effect

Photobiomodulation Therapy in the Prevention and Management of Radiotherapy-induced Vaginal Toxicity

GynLight
Start date: August 24, 2022
Phase: N/A
Study type: Interventional

This study aims to investigate the effectiveness of photobiomodulation therapy (PBMT) in the prevention and management of radiotherapy-induced vaginal toxicity (RIVT). Therefore, we hypothesize that PBMT can reduce the severity of RIVT in gynecological cancer patients, increasing the patient's QoL and sexual functioning.

NCT ID: NCT03547089 Suspended - Sexual Dysfunction Clinical Trials

A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes

BRAVO
Start date: August 1, 2018
Phase: N/A
Study type: Interventional

The focus of this study is to assess breast cancer survivors perspectives of Viveve® Treatment using patient reported outcome tools with a focus on symptoms associated with vulvovaginal atrophy/genitourinary syndrome of menopause (GSM). This will be assessed by the FSFI, FSDS-R and DIVA questionnaires.

NCT ID: NCT03185169 Terminated - Clinical trials for Breast Cancer Female

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

GSM
Start date: November 18, 2016
Phase: Early Phase 1
Study type: Interventional

The impact of treatment for GSM on the quality of life will be examined for postmenopausal women (defined as last menstrual period > 1 year ago or 6 months ago with FSH >40) who have been diagnosed with breast cancer.